Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1952 1
1953 1
1961 1
1963 1
1964 1
1965 4
1966 2
1967 1
1968 1
1969 3
1972 1
1973 1
1974 1
1975 1
1976 4
1977 5
1978 6
1979 9
1980 3
1981 6
1982 4
1983 8
1984 4
1985 7
1986 6
1987 6
1988 3
1989 6
1990 13
1991 13
1992 8
1993 10
1994 14
1995 25
1996 17
1997 20
1998 17
1999 32
2000 42
2001 30
2002 33
2003 38
2004 54
2005 35
2006 50
2007 45
2008 48
2009 46
2010 47
2011 43
2012 41
2013 54
2014 69
2015 54
2016 58
2017 58
2018 47
2019 42
2020 63
2021 77
2022 80
2023 63
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,384 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. Among authors: arakawa y. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. Jo U, et al. Among authors: arakawa y. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102. doi: 10.1158/1535-7163.MCT-21-1000. Mol Cancer Ther. 2022. PMID: 35439320 Free PMC article.
Preclinical Models of Adrenocortical Cancer.
Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J. Sedlack AJH, et al. Among authors: arakawa y. Cancers (Basel). 2023 May 23;15(11):2873. doi: 10.3390/cancers15112873. Cancers (Basel). 2023. PMID: 37296836 Free PMC article. Review.
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: arakawa y. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.
Sun Y, Baechler SA, Zhang X, Kumar S, Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, Su YP, Chen J, Ting T, Huang SN, Beck E, Itkin Z, McKnight C, Xie C, Roper N, Nijhawan D, Figg WD, Meltzer PS, Yang JC, Thomas CJ, Pommier Y. Sun Y, et al. Among authors: arakawa y. Nat Commun. 2023 Jun 23;14(1):3762. doi: 10.1038/s41467-023-39374-9. Nat Commun. 2023. PMID: 37353483 Free PMC article.
Tracheitis Associated with COVID-19.
Ohnishi H, Arakawa Y, Anabuki K, Yokoyama A. Ohnishi H, et al. Among authors: arakawa y. Intern Med. 2023 Jun 1;62(11):1697-1698. doi: 10.2169/internalmedicine.1350-22. Epub 2023 Mar 22. Intern Med. 2023. PMID: 36948623 Free PMC article. No abstract available.
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Koga T, Sasaki N, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Nakamura S, Kojima M, Tamaru JI, Tsuchiya K, Gomyo M, Abe K, Natsumeda M, Yamasaki F, Katayama H, Fukuda H. Mishima K, et al. Among authors: arakawa y. Neuro Oncol. 2023 Apr 6;25(4):687-698. doi: 10.1093/neuonc/noac246. Neuro Oncol. 2023. PMID: 36334050 Free PMC article. Clinical Trial.
1,384 results